Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anlon HealthcareNSE:AHCL -1.10%21 Earnings Yield (Joel Greenblatt) % is 175.44% as of Jun. 2026, which is 1921% above its 10-year median of 8.68. GuruFocus rates NSE:AHCL with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Anlon Healthcare ranks better than 99.6% on this metric.
Anlon Healthcare's Enterprise Value for the quarter that ended in Jun. 2026 was ₹8,499 Mil.
Anlon Healthcare's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was ₹14,850 Mil. Anlon Healthcare's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 175.44%.
The historical rank and industry rank for Anlon Healthcare's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
NSE:AHCL'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.05 Med: 8.68 Max: 257.34
Current: 179.25
During the past 5 years, the highest Earnings Yield (Joel Greenblatt) of Anlon Healthcare was 257.34%. The lowest was 4.05%. And the median was 8.68%.
NSE:AHCL's Earnings Yield (Joel Greenblatt) % is ranked better than 99.6% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.14
vs NSE:AHCL: 179.25
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Anlon Healthcare's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Anlon Healthcare Earnings Yield (Joel Greenblatt) % Related Terms
Anlon Healthcare Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Anlon Healthcare's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:AHCL vs ZTS: Earnings Yield (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Anlon Healthcares Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
Anlon Healthcare's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹14,850 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 175.44% mean?
Anlon Healthcare (NSE:AHCL) has a Earnings Yield (Joel Greenblatt) % of 175.44% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Anlon Healthcare and its competitors. This is 1921% above median its historical median of 8.68. Over the past decade, Anlon Healthcare's Earnings Yield (Joel Greenblatt) % has ranged from 4.05 to 257.34. According to the industry distribution chart, Anlon Healthcare ranks #4 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Anlon Healthcare's Earnings Yield (Joel Greenblatt) % too high?
Anlon Healthcare's current Earnings Yield (Joel Greenblatt) % of 175.44% is 1921% above median its 10-year median of 8.68. Over the past 10 years, this metric has ranged from a low of 4.05 to a high of 257.34. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.14. Anlon Healthcare's value of 175.44% is 5487.3% above this industry median. Based on the distribution chart, Anlon Healthcare ranks #4 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Anlon Healthcare has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's Earnings Yield (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #4 out of 1007 companies for Earnings Yield (Joel Greenblatt) %. This places Anlon Healthcare in the top 0% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.14. Anlon Healthcare's value of 175.44% is 5487.3% above this benchmark. Historically, Anlon Healthcare's own Earnings Yield (Joel Greenblatt) % has ranged from 4.05 to 257.34 over the past decade. While the company's 10-year median is 8.68 vs. the industry median of 3.14, Anlon Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.14, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current Earnings Yield (Joel Greenblatt) % of 175.44% is 5487.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Anlon Healthcare and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current Earnings Yield (Joel Greenblatt) % is 175.44%, which is 1921% above median its own 10-year median of 8.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current Earnings Yield (Joel Greenblatt) % of 175.44%. The current Earnings Yield (Joel Greenblatt) % is 175.44%, which is 1921% above median its 10-year median of 8.68 and 5487.3% above the Drug Manufacturers industry median of 3.14. Anlon Healthcare's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current Earnings Yield (Joel Greenblatt) % is 175.44% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
21GF Score
Get the complete analysis for NSE:AHCL
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
